Retracted: Effect of Fasudil on remyelination following cuprizone-induced demyelination

Jing Wang1 | Ruo-Xuan Sui2 | Qiang Miao2 | Qing Wang2 | Li-Juan Song2 | Jie-Zhong Yu3 | Yan-Hua Li3 | Bao-Guo Xiao4 | Cun-Gen Ma1,2,3

1Department of Neurology, First Affiliated Hospital, Shanxi Medical University, Taiyuan, China
2The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine, Shanxi University of Traditional Chinese Medicine, Taiyuan, China
3Institute of Brain Science, ShanxiDatong University, Datong, China
4Institute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China

Correspondence
Bao-Guo Xiao, Institute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200025, China.
Email: bgxiao@shmu.edu.cn
Cun-Gen Ma, Department of Neurology, First Affiliated Hospital, Shanxi Medical University, Taiyuan 030001, China.
Email: macugen2001@163.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81473577, 81371414 and 2014-7; Shanxi Scholarship Council of China

Abstract
Background: Multiple sclerosis is characterized by demyelination/remyelination, neuroinflammation, and neurodegeneration. Cuprizone (CPZ)-induced toxic demyelination is an experimental animal model commonly used to study demyelination and remyelination in the central nervous system. Fasudil is one of the most thoroughly studied Rho kinase inhibitors.

Methods: Following CPZ exposure, the degree of demyelination in the brain of male C57BL/6 mice was assessed by Luxol fast blue, Black Gold II, myelin basic protein immunofluorescent staining, and Western blot. The effect of Fasudil on behavioral change was determined using elevated plus maze test and pole test. The possible mechanisms of Fasudil action were examined by immunohistochemistry, flow cytometry, ELISA, and dot blot.

Results: Fasudil improved behavioral abnormalities, inhibited microglia-mediated neuroinflammation, and promoted astrocyte-derived nerve growth factor and ciliary neurotrophic factor, which should contribute to protection and regeneration of oligodendrocytes. In addition, Fasudil inhibited the production of myelin oligodendrocyte glycoprotein antibody and the infiltration of peripheral CD4+ T cells and CD68+ macrophages, which appears to be related to the integrity of the blood-brain barrier.

Conclusion: These results provide evidence for the therapeutic potential of Fasudil in CPZ-induced demyelination. However, how Fasudil acts on microglia, astrocytes, and immune cells remains to be further explored.

KEYWORDS
cuprizone-induced demyelination, Fasudil, remyelination, Rho kinase

1 INTRODUCTION

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system (CNS) affecting young adults, which involves innate and adaptive immune responses.1 The pathological characteristics of MS include oligodendrocyte death, demyelination, axonal degeneration, and peripheral immune cell infiltration.2 Although a better understanding of MS has increased our acquaintance of the pathogenesis and pathophysiology of the disease, the exploration of treatment is still challenging. Immune-modulating drugs currently used in the treatment of MS include interferon beta (IFN-β), glatiramer acetate, natalizumab, and fingolimod and has
given little evidence of effectiveness for promoting repair. In general, the treatment of these drugs is primarily aimed at reducing the relapses and slowing the development of disability. To date, no MS therapy has shown any significant ability to improve functioning in patients with fixed disability.

Fasudil, one of the most thoroughly studied Rho kinase (ROCK) inhibitors, has been shown to have beneficial effects in various neurodegenerative diseases. More importantly, previous studies by our group and others have demonstrated that Fasudil exhibited protective effect in models of Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Huntington disease, and spinal muscular atrophy (SMA). These evidences indicate that Fasudil has a wide application prospect in central and peripheral nervous system. However, the role of Fasudil on myelin repair has not been evaluated. The demyelination model induced by cuprizone (CPZ), known as one of the toxic-based demyelination models, is often used to mimic the pathology of human MS. The CPZ induces demyelination in the corpus callosum, superior cerebellar peduncles, and cerebral cortex by selective loss of oligodendrocytes. Remarkably, some aspects of the histological pattern in CPZ-induced demyelination are similar to those found in MS A number of researches have indicated that CPZ exposure also provokes abnormal behaviors, and mood and cognitive deficits that are believed to be a direct result of demyelination.

Thus, CPZ-induced demyelination shows significant relevance for reproducing some key features of demyelinating diseases and can be used as a tool for analyzing mechanisms of demyelination/remyelination and testing the potential therapeutics. The aim of the present study was to investigate the therapeutic effect of Fasudil in CPZ-induced demyelination and to explore the underlying mechanisms of remyelination and/or neuroprotection.

2 | MATERIALS AND METHODS

2.1 | Animals

A total of 24 male C57BL/6 mice (10-12 weeks old) were purchased from Vital River Laboratory Animal Technology Co., Ltd. All animal procedures were performed in accordance with the guidelines approved by the International Council for Laboratory Animal Science. This study was approved by the Council for Laboratory and Ethics Committee of Shanxi University of Traditional Chinese medicine, Taiyuan, China. All mice were maintained and housed under pathogen-free conditions with constant temperature (25 ± 2°C) in a reversed 12:12 hour light/dark cycle.

2.2 | CPZ-induced demyelination

Mice were fed with standard diet or chow diet supplemented with 0.2% (w/w) CPZ (Sigma-Aldrich) ad libitum for a total of 6 weeks to induce demyelination. Mice were randomly divided into three groups (n = 8 each group): (a) normal group fed standard diet; (b) CPZ group fed CPZ and intraperitoneally (ip) injected with normal saline (NS 200 μL) after 4 weeks for consecutive 13 days; (c) Fasudil-treated CPZ group, which were ip injected with Fasudil (40 mg/kg/d) after 4 weeks for consecutive 13 days. Fasudil (from Tianjin Chase Sun Pharmaceutical Co., Ltd) was dissolved in NS. The body weight of mice was monitored every two days. For simplicity of presentation, the normal group, CPZ group, and Fasudil-treated CPZ group will be described as normal, CPZ, and Fasudil, respectively.

2.3 | Behavioral tests

The behavior of mice was assessed by elevated plus maze (EPM) test and pole test at the end of the 6th week of experiment. Elevated plus maze is one of the most widely used tests for measuring anxiety-like behavior by avoiding the open arms of the plus maze. Each mouse was positioned in the center area facing an open arm at first and allowed to move at liberty during the testing. The mouse’s entry into any of the four arms was calculated manually and evaluated when all four paws crossed from the central region into an arm. The number of total arm entries and the amount of time spent on the open arms during a 10-minute testing period were recorded by video.

Pole test was used to assess the locomotor coordination of mice. After the end of the 6th week, each mice was placed tenderly head-up facing the apex of the vertical pole. The time taken to reach the bottom of the pole after climbing over (touchdown time) was recorded for analysis. The cut-off time was 60 seconds for touchdown time. In every test, two consecutive trials were conducted and the average time of two trials was recorded.

2.4 | Tissue preparation

At the end of the experiment, half of the mice in each group were deeply anaesthetized and then perfused transcardially with saline, followed by 4% paraformaldehyde (PFA) in phosphate buffer (PBS, 0.01 M, pH = 7.4). Brains were isolated carefully and postfixed in the same PFA for 2 hours at 4°C. Afterward, brains were treated with 30% w/v sucrose solution at 4°C for 24 hours and embedded with OCT. Brain coronal sections were sliced using a cryostat microtome (Leica CM1850) at a thickness of 10 μm for immunofluorescence procedure. The rest of mice in each group were deeply anaesthetized and perfused transcardially with saline, without 4% PFA. Brains were removed, and the corpus callosums were dissected out. The samples were collected for ELISA and Western blot.

2.5 | Myelin staining

Luxol fast blue (LFB) staining: LFB staining was used to examine the area of demyelination in corpus callosum according to the previous researches. The slides were incubated in 0.1% LFB solution for 18 hours at 60°C. Excess dye was washed away, and slides were hydrated with 95% ethanol. After differentiated by 0.05% lithium carbonate solution for 30 seconds, slices were dipped in 70% alcohol, and stopped immediately with distilled water. Thereafter, slides were dehydrated in a graded ethanol and fixed by dimethylbenzene.
The slides were scanned and captured using a light microscope equipped with a digital camera (Leica camera). ImageJ software was used to evaluate the extent of demyelination.

Black Gold II staining: The Black Gold II staining (Black Gold II myelin staining kit, Millipore) is widely used for visualizing myelin morphology with good resolution of individual myelin fibers. In short, prewarmed Black Gold II solution (0.3% in NS) was added onto 4% PFA-fixed sections and incubated at 60°C in water bath for 25 minutes until desired signals developed. The slides were then fixed in preheated 1% sodium thiosulfate (1% in ddH2O) at 60°C for 3 minutes. After rinsing with Milli-Q water, the slides were incubated with 0.1% Cresyl Violet at RT for 3 minutes. Slides were dehydrated using a series of graded alcohols, cleared in xylene for 2 minutes, and coverslipped with mounting media. The area of demyelination in the corpus callosum was measured using Image Pro Plus software (Media Cybernetics) and represented as percent demyelination.

Myelin basic protein (MBP) immunohistochemistry staining: The slides were blocked with 1% BSA/PBS at RT for 0.5 hours and incubated with anti-MBP (1:500, Abcam) overnight at 4°C, followed by incubation with corresponding secondary antibody at RT for 2 hours. As a negative control, additional slides were treated similarly, but the primary antibodies were omitted. Results were determined using Image-Pro Plus software in a blinded fashion. Quantification was performed on three sections per mouse.

2.6 | Preparation of splenic mononuclear cells

At the end of experiment, fresh spleens were isolated under aseptic conditions. The weight and volume of spleens were recorded. Suspensions of mononuclear cells (MNCs) were prepared by passing the tissue through a 40-µm nylon mesh in medium. Erythrocytes in the suspensions were osmotically lysed. Collected splenocytes were washed twice in PBS, counted, and reconstituted in the complete medium at a concentration of 5 x 10^6/mL. Cells were incubated in the presence or absence of mouse myelin oligodendrocyte glycoprotein peptide 35-55 (MOG 35-55, 10 μg/mL, Bio-Scientific Company) at 37°C for 48 hours.

2.7 | Flow cytometry analysis

Splenic MNCs were fixed with 4% PFA for 20 minutes and then stained in 1% BSA-PBS (surface antigen) or 0.3% saponin/1% BSA-PBS (intracellular staining) for 20 minutes at RT with the following antibodies: Alexa Fluor B220, FITC-CD4/PE-IFN-γ, and CD4/PE-IL-17 (eBioscience). At least 10 000 events were collected using flow cytometer (BD Biosciences), and data were analyzed using Cell Quest software.

2.8 | MOG antibody assay

ELISA method: The blood was collected from the orbit of the mice and centrifuged at 1006 g at 4°C for 10 min. Splenic MNCs were incubated in the presence or absence of MOG 35-55 (10 μg/mL) for 48 hours, and culture supernatants were obtained. The extract of brain tissue was collected after homogenate and centrifugation. MOG 35-55 (10 μg/mL) dissolved in PBS (pH 7.4) was coated in 96 wells overnight at RT. After washing with PBST, wells were blocked with 1% BSA/PBS for 1 hour at RT. Diluted samples (serum = 1:50 and 1:200, brain extract = 1:500) were added and remained at RT for 2 hours. Then, HRP-conjugated anti-mouse IgG was added at RT 1 hour, and OD value (at 450 nm) was recorded.

Dot blot method: MOG 35-55 and α-synuclein (α-syn) 124-140 (1 μg/10 μL) dissolved in PBS (pH 7.4) were coated onto a nitrocellulose membrane (Millipore) for 30 minutes at RT. After washing with PBST, the wells were blocked with 1% BSA/PBS for 1 hour at RT. Serum and culture supernatants (1:50 and 1:200) were added and remained at RT for 2 hours. Then, HRP-conjugated anti-mouse IgG was added at RT for 1 hour. Immunoblots were developed with an enhanced chemiluminescence system (GE Healthcare Life Sciences) and analyzed using Quantity Software (Bio-Rad).

2.9 | Immunohistochemical staining

Brain coronal sections were used to perform immunohistochemical staining. Nonspecific binding was blocked with 1% bovine serum albumin/PBS (BSA, Sigma) for 30 minutes at RT. Subsequently, sections were incubated at 4°C overnight with primary antibodies as follows: anti-O4 (1:500, Abcam), anti-CD4 (1:200, Abcam), anti-CD68 (1:200, Abcam), anti-occludin (1:400, Bioworld), anti-ZO-1 (1:400, Bioworld), anti-Iba-1 (1:200, Abcam), anti-iNOS (1:200, BD), anti-NF-kB (1:200, Abcam), anti-GFAP (1:1000, Abcam), anti-NGF (1:1:300, Abcam), anti-CNTF (1:300, Abcam), and anti-NG2 (1:500, Millipore). Subsequently, sections were incubated with Alexa Fluor 488/555-conjugated secondary antibodies at RT for 2 hours. The fluorescent staining was visualized under fluorescent microscopy and analyzed by Image-Pro Plus software in a blinded fashion. Quantification was performed on three sections per mouse.

2.10 | Western blot analysis

RIPA lysis buffer (Beyotime Institute of Biotechnology) was used to extract protein from brains. Following centrifugation at 12 000 g for 20 minutes at 4°C, the extract was collected, and protein concentration was determined by BCA kit (Beyotime Institute of Biotechnology). Total 30 μg of protein was separated on 10% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (Millipore) after electrophoresis. The membranes were blocked with 5% nonfat dry milk at RT for 1 hour before incubation at 4°C overnight with the following primary antibodies: anti-MBP (Abcam) and anti-β-actin (Cell Signaling Technology). The following day, the membranes were incubated with HRP-conjugated secondary antibody (Earthox LLC) for 2 hours at RT. Immunoblots were developed with an enhanced chemiluminescence system (GE Healthcare Life Sciences) and analyzed using Quantity Software (Bio-Rad). The expression of interest proteins was analyzed by normalizing to the expression of the internal control (β-actin).
2.11 | Cytokine ELISA

The concentrations of IFN-γ, IL-10, IL-17, IL-6, TNF-α (PeproTech Inc), and IL-1β (Invitrogen Inc) were measured by a sandwich ELISA kits following the manufacturer’s instructions. Determinations were performed in at least three independent experiments, and the concentrations of cytokines were expressed as pg/mL.

2.12 | Data analysis

For all experiments, the animals were assigned to different group by random selection. The experiments in this study were repeated two or three times. All statistical analyses were performed by one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc test for multiple comparisons using GraphPad Prism 5 software (Cabit Information Technology Co., Ltd.). Results are expressed as the mean ± SEM. P value <0.05 was considered statistically significant.

3 | RESULTS

3.1 | Establishment of CPZ-induced demyelination model

The CPZ model is an established mouse model of experimental demyelination by selective apoptosis of oligodendrocytes, which peaks around 2-3 weeks of exposure followed by massive loss of myelin at 4-5 weeks. In the current study, mice were first fed with a normal diet or chow diet supplemented with 0.2% (w/w) CPZ for 4 weeks before Fasudil treatment (Figure 1A). Cuprizone feeding significantly decreased the body weight of mice compared to mice with normal diet in the first week after CPZ feeding (Figure 1B). In the following 3 weeks, the body weight of mice in CPZ-fed group still maintained a stable low level (Figure 1B). To determine the demyelination induced by CPZ, brain sections were stained with Black Gold II after a 4-week CPZ feeding. The results showed that the intensity of Black Gold II staining in the corpus callosum, septal nuclei, and cortex was obviously decreased, as compared to mice with normal diet (Figure 1C), demonstrating a demyelinating response to CPZ at the time point for
Fasudil treatment. On this basis, the administration of Fasudil was started for two consecutive weeks.

3.2 | The improvement of behavior and demyelination by Fasudil

To investigate the therapeutic potential of Fasudil in CPZ-induced demyelination, mice were ip injected with Fasudil at 4th week of CPZ diet (Figure 2A). In CPZ-fed mice, body weight of mice decreased significantly within a week of feeding, but Fasudil treatment did not effectively increase body weight of mice at 2nd to 6th weeks as compared with the CPZ group (Figure 2B). Elevated plus maze test showed that CPZ feeding increased the time spent in the closed arm, reflecting increased anxiety, as compared to mice with normal diet (Figure 2C, *P < 0.001). Fasudil treatment improved the anxious behaviors by decreasing the time spent in the closed arm compared to the CPZ group (Figure 2C, *P < 0.05). In addition, pole test showed that CPZ feeding increased the time spent on touchdown (Figure 2C, *P < 0.05, **P < 0.01, ***P < 0.001).
P < 0.01), which was significantly shortened by Fasudil treatment compared to the CPZ group (Figure 2C, P < 0.05). After the behavioral test, mice were decapitated and brain tissues were collected to detect pathologic change.

The effects of Fasudil on the improvement of demyelination were examined by Black Gold II staining, LFB staining, and MBP immunostaining. In CPZ group, both LFB and Black Gold II staining in the corpus callosum was significantly weaker than in normal group (Figure 2D, P < 0.001, respectively). Similarly, CPZ feeding reduced the expression of MBP in the cingulum (Figure 2D, P < 0.001) and by western blot (Figure 2E, P < 0.001) as compared with normal group. These results demonstrated an evident damage of myelin occurred in the corpus callosum and cingulum after 6 weeks of CPZ feeding, which should be related to behavioral changes.

**FIGURE 3**  Fasudil inhibited MOG antibody and improved the integrity of BBB. A, Planar map of spleen size (middle). Left side = ruler and right = weight and number of splenocytes. B, The concentration of MOG antibody in serum and supernatants of cultured splenocytes by ELISA. C, Expression of occludin and ZO-1 (yellow arrow) in the brain by immunohistochemistry. Scale bar = 50 μm. D, The concentration of MOG antibody in extract of brain by ELISA. E, The concentration of MOG antibody in serum (1:50 and 1:200) by dot blot. F, The specificity of the MOG antibody, with MOG35-55 and α-synuclein124-140 for coating antigen by dot blot. G, The population of B220+ B cells in splenocytes by flow cytometry. Quantitative data are mean ± SEM and analyzed for four mice in each group. Photographs are representative maps of mice brain from different groups. *P < 0.05, **P < 0.01, ***P < 0.001
Fasudil treatment significantly protected myelin damage or promoted myelin regeneration, representing an increase in both LFB and Black Gold II staining (Figure 2D, P < 0.001, respectively) and MBP expression by immunohistochemistry staining (Figure 2D, P < 0.05) and western blot (Figure 2E, P < 0.001), as compared to CPZ-fed group. To further understand the effect of Fasudil on the oligodendrocytes, mature oligodendrocytes were counted by O4 immunostaining. As shown in Figure 2F, the number of O4+ mature oligodendrocyte showed a decrease in mice fed with CPZ (P < 0.001). On the contrary, the increase in O4+ oligodendrocyte was found at 2 weeks of Fasudil treatment compared to CPZ group (Figure 2F, P < 0.001). These results suggested that Fasudil treatment ameliorated the behavioral changes and promoted the myelin protection/regeneration in CPZ-mediated demyelination lesion. However, myelin repair in Fasudil-treated mice did not accompany with the increase in body weight at the same time.

### 3.3 The regain of spleen volume by Fasudil

Unexpectedly, the spleen size in CPZ-fed mice was remarkably reduced, and the weight of spleens and the number of splenic MNCs were reduced when compared to normal mice (Figure 3A, P < 0.001). However, Fasudil treatment significantly increased the volume and weight of spleens, and number of splenic MNCs (Figure 3A, P < 0.05).

### 3.4 The inhibition of MOG-specific antibody by Fasudil

It is noteworthy that the presence of serum autoantibodies to CNS-specific proteins was observed in a group of neural or demyelinating injury diseases. Due to the vulnerability of oligodendrocytes in CPZ model, we detected MOG-specific antibody in serum, culture supernatants, and brain homogenates. As demonstrated in

---

**Figure 4** Fasudil basically did not affect the T cell responses. A, The population of CD4+IFN-γ+ and CD4+IL-17+ T cells in splenocytes by flow cytometry. B, The level of cytokine IFN-γ, IL-10, and IL-17 in supernatant of cultured splenocytes by ELISA. C, The level of cytokine IFN-γ, IL-10, and IL-17 in extract of brain by ELISA. Results are expressed as pg/mL. Quantitative data are mean ± SEM and analyzed for four mice in each group. *P < 0.05, **P < 0.01
To observe the integrity of blood-brain barrier (BBB) in CPZ model, we detected the expression of tight junction protein occludin and ZO-1. The results showed that CPZ feeding significantly reduced the expression of occludin and ZO-1 in the brain (Figure 3C, *P < 0.01 and 0.001*, respectively), which increased by Fasudil treatment (Figure 3C, *P < 0.05 and 0.01*, respectively). Compared to normal mice, the MOG antibody in the brain homogenate was significantly increased after CPZ exposure (Figure 3D, *P < 0.05*), revealing that MOG antibody produced in the periphery can enter into the brain. Fasudil treatment inhibited the level of MOG antibody in brain homogenate, although it did not reach the statistical significance. These results revealed that the integrity of BBB may be impaired in CPZ-induced demyelination model.

To compare the results of MOG antibody from ELISA, we also used dot blot assay. In accordance with the results by ELISA, CPZ feeding produced MOG antibody in serum (Figure 3E, *P < 0.001*, respectively), which was inhibited by Fasudil treatment (Figure 3E, *P < 0.001*, respectively). We further tested the specificity of the MOG35-55 antibody, with MOG35-55 and α-synuclein124-140 for coating antigen. The results showed that only MOG antibody in serum of CPZ-fed mice was positive. In contrast, α-synuclein antibody was negative (Figure 3F), demonstrating that CPZ-fed mice produced specific antibody against oligodendrocyte components. Besides, the proportion of CD220+ B cells in splenocytes from CPZ-fed mice (Figure 3G, *P < 0.001*), which can be declined by Fasudil treatment (Figure 3G, *P < 0.001*).

Simultaneously, we measured the proportion of CD4+ T cell subsets and concentrations of T cell-related cytokine IFN-γ, IL-10, and IL-17 in culture supernatants and brain extract. Compared to CPZ group, CD4+IFN-γ+ T cells, not CD4+IL-17+ T cells, were decreased (Figure 4A, *P < 0.01*). Fasudil treatment declined CD4+IL-17+ T cells (Figure 4A, *P < 0.01*), but did not affect CD4+IFN-γ+ T cells. The levels of IFN-γ, IL-10, and IL-17 in culture supernatants and brain extract were not affected by CPZ feeding or Fasudil treatment (Figure 4B), except that IL-10 increased slightly in brain extract of CPZ group (Figure 4C, *P < 0.05*). Immunohistochemical staining showed that a small number of infiltrating CD4+ T cells and CD68+ macrophages around the cerebrovascular were observed in CPZ-fed mice (Figure 5, *P < 0.001*), which was inhibited by Fasudil treatment (Figure 5, *P < 0.001*). These results demonstrated that CPZ feeding and Fasudil treatment did not influence T cell responses in CPZ-fed demyelinating model.

### 3.5 The inhibition of neuroinflammation in the brain by Fasudil

The CPZ model is characterized by primary and reversible demyelination, due to peripheral immune-independent myelin injury, accompanied by mature oligodendrocyte damage and activation of microglia. Previous studies showed that oligodendrocytes are highly vulnerable in an inflammatory microenvironment. Therefore, the neuroinflammation is considered to worsen the severity of demyelinating disease. The formation of neuroinflammation may be due to two sources: (a) the infiltration of peripheral immune cells; and (b) the activation of microglia in the brain.

Immunohistochemical staining demonstrated that CPZ feeding increased the numbers of Iba1-positive cells in the corpus callosum and striatum compared to normal group (Figure 6A, *P < 0.001*), which was inhibited by Fasudil treatment (Figure 6A, *P < 0.001*), indicating that microglia were activated in CPZ-fed mice.

**INOS is an important marker of inflammatory M1 microglia, while NF-κB is the major inflammatory signaling pathway in microglia.** Histological co-staining revealed that the numbers of Iba1+INOS” and Iba1”NF-κB” microglia were increased in the striatum of mice fed with CPZ, as compared to normal group (Figure 6B,C, *P < 0.001*, respectively), which was declined by Fasudil treatment (Figure 6B,C, *P < 0.001* respectively), confirming the anti-inflammatory effect of Fasudil through inhibiting microglia activation and/or M1 polarization in CPZ-induced demyelination.

The activation of inflammatory microglia is known to release inflammatory cytokines. Given that, we wondered whether there was
an association between the microglia phenotype and inflammatory cytokines. As shown in Figure 6D, the levels of main inflammatory cytokines IL-1β and IL-6 were elevated in CPZ-fed mice ($P < 0.001$ respectively), which was inhibited by Fasudil treatment ($P < 0.001$, respectively). The change of TNF-α had similar trend, though the difference did not reach statistical significance (Figure 6D). These
results indicated that CPZ-induced demyelination is associated with neuroinflammation caused by the activation of M1 microglia, which can be suppressed by the treatment of Fasudil.

3.6 | The induction of neurotrophic environment in the brain by Fasudil

Neurotrophin signaling impacts development and survival of oligodendrocyte lineage cells. In this study, we find that CPZ feeding resulted in the enrichment and increase in GFAP⁺ astrocytes in the corpus callosum and striatum compared to normal group, which can be further enhanced by Fasudil treatment (Figure 7A), revealing that Fasudil plays an important role on astrocytes. Immunohistochemical double staining indicated Fasudil promoted the expression of NGF and CNTF on GFAP⁺ astrocytes (Figure 7B). The neurotrophic environment contributes to the survival and regeneration of oligodendrocytes in CPZ-induced demyelination. As expected, Fasudil promoted the generation of NG⁺ oligodendrocytes (Figure 7C). These results hypothesized that the Fasudil induced the production of astrocyte-derived NGF and CNTF is beneficial for the survival and regeneration of oligodendrocytes in demyelinating model.

4 | DISCUSSION

Previous works have indicated that Fasudil has neuroprotective effects in several neurodegenerative diseases, like experimental autoimmune encephalomyelitis (EAE), PD, ALS, and AD. The mechanisms of Fasudil action include anti-inflammatory, synaptogenesis, and M2 polarization in microglia. In addition, Fasudil ameliorated the severity of EAE, accompanied by rebalance of helper T cell 1 (Th1) and Th17, macrophage polarization from M1 to M2 phenotype, and less infiltration of inflammatory cells in spinal cord. By regulating peripheral immune dysfunction, Fasudil attenuated neuroinflammation, demyelination, and axonal loss in EAE model. In the present study, we demonstrated that CPZ feeding resulted in the demyelination in fourth weeks, indicating that CPZ-induced demyelinating model was successfully established at the time point for Fasudil treatment. Fasudil promoted remyelination in the corpus callosum, reduced oligodendrocyte damage/loss in the striatum, and improved motor dysfunction possibly through the following two actions: (a) the inhibition of microglia-mediated inflammatory microenvironment, thereby protecting myelin sheath; (b) the production of astrocyte-derived NGF and CNTF, thereby promoting the formation of NG⁺ oligodendrocytes.
The spleen is one of the most important peripheral immune organs, which is frequently affected in infectious diseases. In this CPZ-induced demyelinating model, spleen atrophy was observed compared to normal mice. To exclude the deviation of spleen atrophy, the weight of spleens and the number of splenocytes were also examined, giving the same results with atrophy of spleen. Consistent with our results, a very recent study also found that CPZ exposure also induced spleen atrophy. At present, we lack direct experimental evidence to elucidate the cellular and molecular mechanisms for spleen atrophy in CPZ-induced demyelination. Previous studies have shown that splenic atrophy is an important feature for stroke-induced peripheral immunodepression within the first few days, which is characterized by reduced organ size and reduced number of spleen cells, and this decrease in spleen size is due to apoptosis of cells and loss of functional centers within spleen. It was reported that patients undergoing acute phase of ischemic stroke (<24 hours) exhibited marked atrophy of spleen, as measured by magnetic resonance imaging (MRI). Further investigation found that catecholamine surge following middle cerebral artery occlusion (MCAO) activated α1-adrenergic receptors on splenic capsule, causing a contraction of smooth muscles in the capsule. Blocking the α1-adrenergic receptors with prazosin or carvedilol prevented the decrease in spleen size seen at 48 hours following MCAO. A great number of studies have shown that splenic atrophy in experimental stroke may contribute to brain injury possibly through the release of inflammatory mediators and spleen-derived inflammatory cells to the circulation and migration into the brain, which aggravate the brain inflammatory response and led to secondary injury. As early as 30 years ago, it has been reported that the weight of spleen in acute EAE was also decreased, but no remarkable changes were observed microscopically except slight reduction of the white pulp. Subsequently, this phenomenon has not attracted further attention. The presence of spleen atrophy in CPZ-induced demyelination may be important for studies of remyelination and demyelination.

Most surprisingly, we for the first time found that CPZ feeding induced the formation of MOG antibody. How do we comprehend that CPZ feeding produced MOG-specific autoantibodies? To answer this question, we first determined whether the BBB is complete in CPZ-induced demyelinating model. Several studies have demonstrated the integrity of the BBB through different methods, including MRI, horseradish peroxidase (HRP) leakage, radioactive tracer leakage, and serum extravasation. Recent study indicated that BBB hyperpermeability precedes demyelination in CPZ-demyelinating model. BBB integrity was compromised in mice treated with CPZ for 4 weeks, as indicated by extravasation of Evans blue dye into the CNS. In addition, the integrity and permeability of BBB depend on tight junctions that are sensitive to disruption triggered by inflammatory mediators. As expected, the expression of occludin and ZO-1 was reduced in CPZ-induced demyelination mice compared to normal mice. Fasudil treatment presented an increase in occludin and ZO-1 in the brain, suggesting that Fasudil improved vascular integrity. If the expression of occludin and ZO-1, MOG antibody, and infiltration of T cells/macrophages in the brain are considered together, it can be speculated that BBB damage may exist in CPZ-induced demyelination model, while Fasudil can improve the integrity of BBB.

Another study suggested that debris of damaged cells in the nervous system may present as antigens after penetrating the BBB, giving rise to autoantibodies. Besides BBB, these antigens can subsequently reach the cervical lymph nodes and palatine tonsils by passing through the cribriform plate and traveling along basement membranes in the walls of capillaries and cerebral arteries, and activate the innate and adaptive arms of the immune system and further stimulate the inflammatory cascade. Traces of myelin have indeed been detected in deep cerebral lymph nodes of patients with MS as well as in mice model of EAE. Therefore, it is possible that myelin debris produced by the destruction of myelin sheath subsequently leak into the blood circulation and stimulate the immune responses of T and B cells.

Despite evidence that MOG antibody was increased in brain of mice fed with CPZ than that of normal mice, it is needed to reveal the origin of autoantibody synthesis (ie, within vs. outside the CNS). We found that MOG antibody was obviously elevated in the supernatant of cultured splenocytes, indicating that the production of MOG antibody was derived from peripheral immune cells. Our results also showed that: (a) the level of MOG antibody in the brain homogenate of CPZ-treated mice was higher than that of normal mice, suggesting that antibody can enter brain tissue; (b) anti-α-syn antibody was negative. These results point out at least two points: (a) anti-MOG antibody is a myelin protein-specific antibody; and (b) there is no evidence that CPZ feeding can also cause the damage to dopaminergic neurons, except demyelination. Here, we are still unable to clarify that autoantibodies are only immune responses caused by myelin debris or, in turn, can further cause cell damage in the CNS. In vivo models showed that B cells and autoantibodies exacerbate tissue damage and impair neurological recovery after spinal cord injury. Antibodies to galactocerebroside (GalC) and MOG can play a major role in destabilizing myelin through MBP breakdown. To date, most data indicate that B cell activation after a traumatic CNS injury, especially spinal cord injury (SCI), causes pathology leading to impaired recovery of neurological function. In the current study, human MS patients have circulating antibodies specific for both human and mouse MOG. MOG-specific antibodies from MS patients can contribute to EAE exacerbation in a transfer model. Our results showed that MOG antibody was capable of being detected in the brain of mice fed with CPZ, providing a possibility for specific MOG antibody-mediated oligodendrocyte damage. Therefore, it is logical to explore inhibition of B cell function as a therapeutic option. Whether MOG antibody is a mere epiphenomenon of brain injury or contributes to the late sequelae of demyelination is unclear. Further investigation remains to be needed, including the antibody-mediated pathology in CPZ-induced demyelination, complement or antibody-dependent cellular cytotoxicity, and mechanism of Fasudil in antibody regulation. Further understanding of antibody-mediated pathology may suggest novel therapeutic strategies in demyelinating disease.
It has been noted that the activation of microglia in numerous researches of CPZ-induced demyelination. In addition, oligodendrocytes are highly vulnerable in an inflammatory environment. 

In this study, we found that Iba-1 microglia were aggregated or increased in the corpus callosum and striatum, demonstrating that CPZ induced microglia activation, which is consistent with other studies. Activated microglia are known to contribute to neurodegeneration via various cytotoxic molecules. On the other hand, activated microglia also could play important roles in protection against various pathological conditions in the CNS. 

iNOS is an important marker of inflammatory M1 microglia, and NF-κB is the major inflammatory signaling pathway in microglia. The activation of inflammatory microglia expressing iNOS and NF-κB contributes to the formation of inflammatory microenvironment and damage of neurons or oligodendrocytes. In accordance with the other results, CPZ induced a wide range of Iba-1 microglia that express iNOS and NF-κB, which was inhibited by Fasudil treatment, revealing that therapeutic effect of Fasudil may be related to its anti-inflammatory role. However, further studies will be needed to determine the exact mechanism of Fasudil in CPZ-induced demyelination.

ROCK is increasingly recognized as critical coordinators of a tissue response to injury due to their ability to modulate a wide range of biological processes. ROCK has different biological effects on different cells. The activation of ROCK causes hypercontraction of smooth muscle by promoting both actomyosin interaction and remodeling of the cytoskeleton. Therefore, ROCK inhibitors are a new class of agents, which may be beneficial in the treatment of a variety of cardiovascular diseases, including angina, cerebral vasospasm, and pulmonary hypertension. Abnormal activity of ROCK associated with an increased inflammatory response was demonstrated in the brain of PD and AD, the treatment of Fasudil skews "M1" toward "M2" microglia and inhibits inflammatory cytokines in experimental EAE, PD, and AD models. Besides, recent studies have defined new functions of ROCKs as a critical component of diverse signaling pathways in neurons. The inhibition of ROCK increases neurite outgrowth and axonal regeneration, being a promising therapeutic option for the treatment of neurodegenerative diseases. In this study, the results also demonstrated that Fasudil promoted oligodendrocyte differentiation and maturation possibly through astrocyte-derived NGF and CNTF.

5 | CONCLUSION

Fasudil exhibited the therapeutic potential in CPZ-mediated demyelination, accompanied by the inhibition of MOG-specific antibody and T cells and macrophage infiltration, as well as the improvement of microglia-mediated neuroinflammation and astrocyte-derived neurotrophic environment. Otherwise, the inhibition of IL-1β, IL-6, and TNF-α appears to regulate the integrity of BBB and the presence of MOG antibody and inflammatory cells in the brain. These data indicate that Fasudil promoted myelin protection and regeneration by multiple mechanisms. However, how Fasudil acts on microglia, astrocytes, and immune cells remains to be further explored.

ACKNOWLEDGMENT

This work was supported by grants from the National Natural Science Foundation of China (No. 81473577 and 81371414) and Research Project Supported by Shanxi Scholarship Council of China (2014-7).

CONFLICT OF INTEREST

The authors declare no financial or commercial conflict of interest.

ORCID

Jing Wang https://orcid.org/0000-0002-4076-9274
Bao-Guo Xiao https://orcid.org/0000-0003-3335-8992

REFERENCES

1. Bauer J, Rauschka H, Lassmann H. Inflammation in the nervous system: the human perspective. Glia. 2001;36(2):235-243.
2. Benn T, Halipenny C, Scolding N. Glial cells as targets for cytotoxic immune mediators. Glia. 2001;36(2):200-211.
3. Mahurkar S, Suppiah V, O’Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev. 2014;13(2):178-186.
4. Roser AE, Tönges L, Lingor P. Modulation of microglial activity by rho-kinase (ROCK) inhibition as therapeutic strategy in Parkinson’s disease and amyotrophic lateral sclerosis. Front Aging Neurosci. 2017;9:94.
5. Koch JC, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018;189:1-21.
6. Song Y, Chen X, Wang LY, Gao W, Zhu MJ. Rho kinase inhibitor Fasudil protects against beta-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther. 2013;19(8):603-610.
7. Li M, Yasumura D, Ma A, et al. Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of Huntington disease. PLoS ONE. 2013;8(2):e56026.
8. Bowerman M, Murray LM, Boyer JG, Anderson CL, Kotthary R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 2012;10:24.
9. Vega-Riquier JM, Mendez-Victoriano G, Morales-Luckie RA, Gonzalez-Perez O. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol. 2019;17(2):129-141.
10. Torkildsen O, Brunborg LA, Myhr KM, Be L. The cuprizone model for demyelination. Acta Neurol Scand Suppl. 2008;188:72-76.
11. Skipułetz T, Lindner M, Kotsiari A, et al. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol. 2008;172(4):1053-1061.
12. Taylor LC, Gilmore W, Ting JP, Matsushima GK. Cuprizone induces similar demyelination in male and female C57BL/6 mice and results in disruption of the estrous cycle. J Neurosci Res. 2010;88(2):391-402.
13. Wang H, Li C, Wang H, et al. Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. Neurosci Bull. 2013;29(2):251-259.
14. Kulkarni SK, Sharma AC. Elevated plus-maze: a novel psychobehavioral tool to measure anxiety in rodents. Methods Find Exp Clin Pharmacol. 1991;13(8):573-577.

15. Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997;73(1):45-48.

16. Margolis G, Pickett JP. New applications of the Luxol fast blue myelin stain. Lab Invest. 1956;5(6):459-474.

17. Schmued L, Bowyer J, Cozart M, Heard D, Binenda Z, Paule M. Introducing Black-Gold II, a highly soluble gold phosphate complex with several unique advantages for the histochemical localization of myelin. Brain Res. 2008;1229:210-217.

18. Yoshikawa K, Palumbo S, Toscano CD, Bosetti F. Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. Prostaglandins Leukot Essent Fatty Acids. 2011;85(1):43-52.

19. Ankeny DP, Popovich PG. B cells and autoantibodies: complex roles in CNS injury. Trends Immunol. 2010;31(9):332-338.

20. Moharregh-Khiabani D, Blank A, Skripuletz T, et al. Effects of fumaric acids on cuprizone induced central nervous system demyelination and remyelination in the mouse. PLoS ONE. 2010;5(7):e11769.

21. Gao Z, Tisirke SE. Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol Res Int. 2011;2011:383087.

22. Tsunoda I, Fujinami RS. Inside-Out versus Outside-In models for virus-induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol. 2002;24(2):105-125.

23. Deb C, Lafrance-Corey RG, Zoecklein L, Papke L, Rodriguez M, Kabuto H. Expanding the repertoire of CNS-reactive T cells in MS patients. J Neuropathol Exp Neurol. 2011;70(1):45-52.

24. Liu C-Y, Guo S-D, Yu J-Z, et al. Fasudil mediates cell therapy of EAE treated with Fasudil. PLoS ONE. 2015;10(8):e0134841.

25. Mahrarreh-Khiabani D, Blank A, Skripuletz T, et al. Effects of fumaric acids on cuprizone induced central nervous system demyelination and remyelination in the mouse. PLoS ONE. 2010;5(7):e11769.

26. Yu J-Z, Chen C, Zhang Q, et al. Changes of synapses in experimental autoimmune encephalomyelitis by using Fasudil. Wound Repair Regen. 2016;24(2):317-327.

27. Zhao YF, Zhang Q, Xi JY, Li YH, Ma CG, Xiao BG. Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease. J Neurol Sci. 2015;353(1-2):28-37.

28. Tatenhorst L, Eckermann K, Danbeck V, et al. Fasudil attenuates aggregation of alpha-synuclein in models of Parkinson's disease. Acta Neuropathol Commun. 2016;4:39.

29. Roser AE, Tonges L, Lingor P. Modulation of microglial activity by rho-kinase (ROCK) inhibition as therapeutic strategy in Parkinson's disease and amyotrophic lateral sclerosis. Front Aging Neurosci. 2017;9:94.

30. Chen C, Yu J-Z, Zhang Q, et al. Role of rho kinase and Fasudil on synaptic plasticity in multiple sclerosis. NeuroMolecular Med. 2015;17(4):454-465.

31. Chen C, Li Y-H, Zhang Q, et al. Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis. Acta pharmacol Sinica. 2014;35(11):1428-1438.

32. Sun X, Minohara M, Kikuchi H, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2006;180(1-2):126-134.

33. Liu Z, Wu YU, Feng Y, et al. Spleen atrophy related immune system changes attributed to infection of Angiostrongylus cantonensis in mouse model. Parasitol Res. 2017;116(2):577-587.

34. Martin NA, Molnar V, Szilagyi GT, et al. Experimental demyelination and axonal loss are reduced in MicroRNA-146a deficient mice. Front Immunol. 2018;9:490.

35. Offner H, Subramanian S, Parker SM, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176(11):6523-6531.

36. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26(5):654-665.

37. Liu Q, Jin W-N, Liu Y, et al. Brain ischemia suppresses immunity in the periphery and brain via different neurogenic innervations. Immunol. 2017;46(3):474-487.

38. Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex. NeuroReport. 2004;15(2):357-361.

39. Ajmo CT, Collier LA, Leonardo CC, et al. Blockade of adenosine receptors inhibits the splenic response to stroke. Exp Neurol. 2009;218(1):47-55.

40. Seifert HA, Leonardo CC, Hall AA, et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis. 2012;27(2):131-141.

41. Seifert HA, Hall AA, Chapman CB, Collier LA, Willing AE, Pennypacker KR. A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation. J Neuroimmune Pharmacol. 2012;7(4):1017-1024.

42. Bao Y, Kim E, Bhosle S, Mehta H, Cho S. A role for spleen monocytes in post-ischemic brain inflammation and injury. J Neuroinflammation. 2010;7:92.

43. Sansom BF, Pattison IH, Jebbett JN. Permeability of blood vessels in mice affected with scrapie or fed with cuprizone. J Comp Pathol. 1973;83(4):461-466.

44. Bakker DA, Ludwin SK. Blood-brain barrier permeability during Cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci. 1987;78(2):125-137.

45. McMahon EJ, Suzuki K, Matsushima GK. Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol. 2002;130(1-2):32-45.

46. Merkler D, Boretius S, Stadelmann C, et al. Multicontrast MRI of remyelination in the central nervous system. NMR Biomed. 2005;18(6):395-403.

47. Berghoff SA, Dücking T, Spieth L, et al. Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model. Acta Neuropathol Commun. 2017;5(1):94.

48. Berghoff SA, Gerndt N, Winchenbach J, et al. Dietary cholesterol promotes repair of demyelinated lesions in the adult brain. Nat Commun. 2017;8:14241.

49. Feng S, Zou L, Wang H, et al. Pathway inhibition and tight junction protein upregulation by catalpol suppresses lipopolysaccharide-induced disruption of blood-brain barrier permeability. Molecules. 2018;23(9):pii E2371.

50. Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8(7):401-410.

51. Fabriek BO, Zwemmer J, Teunissen CE, et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol. 2005;161(1-2):190-194.

52. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996;6(3):275-288.

53. Ankeny DP, Guan Z, Popovich PG. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest. 2009;119(10):2990-2999.
54. Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem. 2006;99(4):1073-1087.

55. Menon KK, Piddlesden SJ, Bernard CC. Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin. J Neurochem. 1997;69(1):214-222.

56. Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmunity. 2017;83:95-112.

57. Higromath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol. 1998;92(1-2):38-49.

58. Hibbits N, Yoshino J, Le TQ, Armstrong RC. Astrogliosis during acute and chronic cuprizone demyelination and implications for remyelination. ASN Neurol. 2012;4(6):393-408.

59. Voš EV, Škuljec J, Gudi V, et al. Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? Neurobiol Dis. 2012;45(1):519-528.

60. Chamberlain KA, Nanesu SE, Pschoulia K, Huang JK. Oligodendrocyte regeneration: its significance in myelin replacement and neuroprotection in multiple sclerosis. Neuropharmacology. 2016;110(Pt B):633-643.

61. Aryanpour R, Pasbakhsh P, Zibara K, et al. Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model. Int Immunopharmacol. 2017;51:131-139.

62. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312-318.

63. Hartmann S, Ridley AJ, Lutz S. The function of rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front Pharmacol. 2015;6:276.

64. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res. 2016;118(2):352-366.

65. Chong CM, Ai N, Lee SM. ROCK in CNS: different roles of isoforms and therapeutic target for neurodegenerative disorders. Curr Drug Targets. 2017;18(4):455-462.

How to cite this article: Wang J, Sui R-X, Miao Q, et al. Retracted: Effect of Fasudil on remyelination following cuprizone-induced demyelination. CNS Neurosci Ther. 2020;26:76-89. https://doi.org/10.1111/cns.13154